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Purified human eosinophils were challenged with N-formyl-methionyl-leucyl-phenylalanine, l ukotriene Bq, 
platelet-activating-factor, valyl-glycyl-seryl-glutamic acid, phorbol myristate acetate, zymosan, opsonized 
zymosan and the calcium ionophore A23187 to induce leukotriene synthesis. Reversed-phase high perfor- 
mance liquid chromatography analysis demonstrated the almost exclusive synthesis of leukotriene C., by 
eosinophils of 11 healthy donors after challenge with opsonized zymosan [(22 +4) x lo6 molecules LTC4/ 
cell, mean f SE] or the calcium ionophore A23 187 [(54 f 7) x lo6 molecules LTCVcell, mean + SE]. The 
other agents were not capable of inducing leukotriene formation. When in addition to opsonized zymosan 
N-formyl-methionyl-leucyl-phenylalanine or platelet-activating factor were added a significant increase of 
the leukotriene Cq synthesis by eosinophils was observed. These results suggest hat eosinophils might be 
triggered to produce considerable amounts of the spasmogenic leukotriene C, in vivo by C3b- and/or IgG- 
mediated mechanisms e.g. phagocytosis. 
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1. INTRODUCTION 
Recently, it has been shown that human 
eosinophils have the capacity to synthesize con- 
siderable amounts of the strongly bronchoconstric- 
tive compound leukotriene Cd (LTC4: 5(s)- 
hydroxy-6(R)-glutathionyl-7,9-trans- 11,14-cis-ei- 
cosatetraenoic acid) when stimulated in vitro with 
the calcium ionophore A23187 [l-3]. Since it has 
also been demonstrated recently that eosinophils 
infiltrate into the bronchioli at the beginning of the 
allergen-induced late-phase asthmatic reaction 
[4,5], both these findings throw new light on the 
role of eosinophils in the pathogenesis of asthma. 
As the late-phase asthmatic reaction is thought to 
be an inflammatory process, eosinophils might 
participate via C3b- and/or IgG-mediated 
mechanisms. In this study we present evidence that 
LTC4 formation by human eosinophils can be in- 
duced via C3b- and/or IgG-mediated mechanisms. 
2. MATERIALS AND METHODS 
2.1. Materials 
Calcium ionophore A23 187, reduced gluta- 
thione, phorbol-12-myristate-13-acetate (PMA), 
valyl-glycyl-seryl-glutamic acid (Val-Gly-Ser-Glu), 
N-formyl-methionyl-leucyl-phenylalanine (fMLP), 
zymosan A, PGB2, 4-hydroxy-2,2,6,6-tetrameth- 
ylpiperidinooxy free radical were purchased from 
Sigma (St. Louis, MO). Ficoll-Paque (1.077 g/ml) 
and Percoll (1.129 g/ml) were obtained from 
Pharmacia (Uppsala, Sweden). Solvents, which 
were all of HPLC quality and octadecyl reversed- 
phase extraction columns (6 ml) were obtained 
from Baker (Phillipsburg, NJ). Synthetic LTB4, 
LTC4 and LTD4 were a kind gift of Dr J. Rokach 
(Merck-Frosst Laboratories, Pointe Claire/ 
Dorval, Quebec, Canada). Human blood was ob- 
tained from healthy volunteers of the Red Cross 
Bloodbank Foundation (Utrecht). 
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2.2. Preparation of opsonized zymosan (OZ) and 
zymosan-activated serum (ZAS) 
Freshly collected serum prepared of blood 
samples of 25 healthy volunteers was pooled and 
stored in fractions of 4 ml at -70°C until use. 
Zymosan was prepared as described by Robinson 
et al. [6]. Briefly: 500 mg of zymosan A is boiled 
in 50 ml phosphate-buffered saline (PBS) for 
60 min. This suspension is washed twice with PBS. 
Batches of 75 mg boiled zymosan are suspended in 
5 ml PBS and stored at -70°C until use. On the 
day of use, a batch of boiled zymosan is thawed 
and centrifuged (10 min, 1500 x gmax, room 
temperature). The pellet is resuspended in 3 ml of 
pooled normal serum and incubated for 30 min at 
37°C. After centrifugation (10 min, 1500 x g,,, 
room temperature), the pellet (OZ) is resuspended 
in 5 ml Dulbecco’s salt solution and kept cool 
(OOC) in the dark until use. The supernatant will be 
referred to as zymosan-activated serum (ZAS). OZ 
is used in a concentration of 5 mg/ml, unless 
otherwise stated. At this concentration no lactate 
dehydrogenase release could be observed. 
2.3. Purification of eosinophils 
Citrated blood was collected and platelet-rich 
plasma removed by centrifugation (15 min, 275 x 
g,,,,, room temperature). Granulocytes and 
mononuclear cells were separated by centrifuga- 
tion of the buffy coat on Ficoll-Paque (20 min, 650 
x gmax, room temperature). The mixed 
granulocytes were collected and the remaining 
erythrocytes removed by isotonic ammonium 
chloride lysis at 0°C and subsequent centrifuga- 
tion. Thereafter the cells were regenerated at 37°C 
in minimum essential medium/lO% fetal calf 
serum for 30 min (pH 7.4 at 37’C). After cen- 
trifugation the cells were resuspended in PBS (pH 
7.4). The eosinophils were purified by subsequent 
centrifugation over isotonic Percoll layers with 
densities 1.082 g/ml and 1.085 g/ml as described 
[2,7]. Almost pure neutrophils appeared at the top 
of the Percoll solution with a density of 
1.082 g/ml. The bottom layer consisted of an 
eosinophil enriched cell suspension. Further 
separation over a Percoll solution with a density of 
1.085 g/ml resulted in an almost pure eosinophilic 
cell preparation on the bottom of the tube. Cell 
purities were generally over 85% and cell in- 
tegrities over 95Yo. 
2.4. Incubation procedure and sample preparation 
Purified eosinophils were suspended in Dulbec- 
co’s salt solution (pH 7.4) at a concentration of 
1 x lo6 cells/ml, preincubated at 37°C for 5 min 
and then incubated for the indicated time period 
with a stimulant in the presence of 1 mM (extra) 
CaClz and 5 mM reduced glutathione. Reactions 
were stopped by the addition of an equal volume 
of ice-cold water (for HPLC) or an equal volume 
of ice-cold LTC4-radioimmunoassay kit buffer 
(for RIA). Then the cells were spun down (20 min, 
2000 x gmax, 4°C) and the supernatant analyzed. 
To samples for RP-HPLC analysis PGB2 was add- 
ed as an internal standard, whereafter the samples 
were brought onto an octadecyl (C18) reversed 
phase extraction column. The adsorbed 
leukotrienes were eluted with 3 ml of methanol 
and stored under nitrogen at -70°C in the 
presence of a radical scavenger until analysis. 
Samples for RIA analysis were stored under 
nitrogen at -70°C until analysis. 
2.5. Analysis of leukotrienes 
2.5.1. By RIA 
A commercially available LTCCRIA (New 
England Nuclear, Boston, MA, USA) was used in 
accordance to the manufacturers instructions. 
LTC4 formation was routinely measured by RIA 
and additionally in some cases by RP-HPLC. 
LTC4 synthesis is expressed as the number of 
LTC4 molecules ynthesized per cell ( lo6 molecules 
LTC4/cell = 1.67 pmol LTC4/106 cells = 1.04 ng 
LTC4/ 1 O6 cells). 
2.5.2. By RP-HPLC 
Leukotrienes were separated and quantified as 
described [8] using a CP Spher lOC18 column 
(250 X 4.6 mm, Chrompack, Middelburg, The 
Netherlands) attached to a Perkin-Elmer series 1 
pump and a LC 85 detector. The solvent system 
was tetrahydrofuran-methanol-water-acetic a id 
(25 : 30 : 45 : 0.1, by vol.) which had been brought to 
pH 5.5 with ammonium hydroxide. The aqueous 
phase contained 0.1% EDTA to prevent binding of 
cations to the column. rQ flow rate of 0.9 ml/min 
was maintained and the effluent was monitored at 
280 nm (leukotrienes, 6 = 40000 M-’ *cm-‘, 
PGB2, l = 28650 M-’ *cm-‘). 
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3. RESULTS 
3.1. LTC4 formation by eosinophils induced 
by OZ 
Isolated eosinophils were challenged for 30 or 
60 min with the following agents to induce LTC4 
synthesis: fMLP (1 nM-1 PM), LTB4 (0.1 nM- 
1 PM), PAF (10 nM-1 pM), Val-Gly-Ser-Glu 
(0.1 nM-1 PM), PMA (10 nM), ZAS (undiluted 
and dilutions 1:3 and 1:9), zymosan 
(0.1-5 mg/ml) and OZ (0.1-10 mg/ml). LTC4 
synthesis could be observed only after challenge 
with OZ. When eosinophils were challenged for 
30 min with OZ (5 mg/ml), (22 f 4) x lo6 
molecules LTCUcell are formed, whereas after 
optimal stimulation of the same cells (20 min) with 
A23187 (lO@M), (54 & 7) x lo6 molecules 
LTC4/cell were formed (n = 11, mean + SE, cell 
purity, 86 + 4%). The time course of LTC4 forma- 
tion by isolated eosinophils when stimulated with 
OZ (5 mg/ml) is shown in fig. 1. Based on the time 
course experiments an incubation time of 60 min 
was chosen to study the stimulant concentration 
dependence of the OZ-induced LTC4 formation. 
In fig.2 it is shown that zymosan particles as such 
are not capable of inducing LTC4 synthesis. OZ- 
induced LTC4 synthesis reaches a plateau after an 
OZ concentration of 2.5 mg/ml. When zymosan 
particles were opsonized with heat-inactivated 
serum (30 min at 56’C) a 90% decrease of the 
LTC4 formation was observed (n = 5). 
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Fig.1. Time course of LTC4 formation by purified 
human eosinophils (purity, 84 f 5%) upon stimulation 
with opsonized zymosan (5 mg/ml) (mean + SE, n = 5). 
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Fig.2. LTC4 formation by purified human eosinophils 
when stimulated for 60 min at 37°C with increasing 
amounts of zymosan particles ((m), mean f SE, n = 3, 
purity of the eosinophils, 83 + 3%) or opsonized 
zymosan particles ((o), mean f SE, n = 7, purity of the 
eosinophils, 86 f 3%). 
0.001 
A280 
I 
F 
PGl32 
I 
0 
I 1 
IO 20 
elution time (mini 
Fig.3. Illustrative example of a RP-HPLC 
chromatogram showing the exclusive formation of 
LTC4 by purified human eosinophils (purity, 87%) 
when stimulated with OZ + PAF for 30 min. LTC4 was 
identified by (1) RP-HPLC retention time, (2) coelution 
with synthetic LTC4 and (3) UV spectrum. 
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Table 1 
LTC4 formation (in lo6 molecules/cell) by human eosinophils after 
stimulation for 30 min with OZ (5 mg/ml), fh4LP (100 nM), PAF (1 pM), 
LTB4 (50 nM), PMA (10 nM) or a combination of OZ with each of the other 
compounds 
Stimulant n Cell purity LTC4 formation Paired t-test 
(mean f SE) (mean + SE) 
oz 14 84 + 3 16 +3 p < 0.001 
oz + fMLP 14 24 +4 
fMLP 14 0.B + 0.1 
oz 11 88 * 2 18 *3 p < 0.05 
OZ + PAF 11 24 *S 
PAF 11 0.7 * 0.1 
oz 6 90*2 21 *4 n.s. 
OZ + LTB4 6 24 f 6a 
LTB4 6 0.3 f 0.1 
oz 4 90 * 1 26 +4 n.s. 
OZ + PMA 4 25 *3 
PMA 4 0.4 f 0.2 
a Extension of the incubation time to 60 min resulted in a more pronounced 
stimulation 
September 1985 
The OZ-induced LTC4 formation by eosinophils 
proved to be completely dependent on the presence 
of both reduced glutathione (5 mM) and CaClz 
(2 mM) in the incubation medium (n = 3). 
Therefore stimulations were always performed in 
the presence of reduced glutathione (5 mM) and 
CaClz (2 mM). 
3.2. Effect of various agents on the LTC4 
formation by eosinophils induced by OZ 
LTC4 formation by eosinophils was measured 
after challenge for 30 min with fMLP (100 nM), 
PAF (1 PM), LTB4 (50 nM) and PMA (10 nM). 
Although these compounds as such did not induce 
LTC4 synthesis by eosinophils, the first two com- 
pounds were found to stimulate the OZ-induced 
LTC4 synthesis ignificantly as is shown in table 1. 
RP-HPLC analysis showed that besides LTC4 
no other leukotrienes are formed by eosinophils 
when stimulated with OZ alone or in combination 
with fMLP, LTB4, PMA or PAF (fig.3). 
4. DISCUSSION 
These results show that OZ is capable of induc- 
ing LTC4 synthesis by human eosinophils and il- 
lustrate that considerable amounts of LTC4 can be 
formed via C3b- and/or IgG-mediated mecha- 
nisms [9]. Since stimulation with zymosan, treated 
with heat-inactivated serum, was found much less 
effective than stimulation with OZ, it. might be 
concluded that the C3b-receptor is more important 
in this process than the IgG-receptor. This is in 
agreement with the small stimulatory effect which 
has been reported for IgG-coated Sepharose- 
particles [lo]. It has been shown that chemotactic 
factors like fMLP and PAF may increase the ex- 
pression of IgG- and C3b-receptors on eosinophils 
[ll-141. This finding might explain the 
stimulatory effect of these compounds on the OZ- 
induced LTC4 formation by eosinophils. Conse- 
quently, PMA, which has no effect on the expres- 
sion of C3b- and IgG-receptors, was found inac- 
tive in this respect. 
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In conclusion, this study shows that human 
eosinophils might be triggered to produce LTC4 by 
C3b- and/or IgG-mediated mechanisms (e.g. 
phagocytosis) and that certain chemotactic agents 
can amplify this effect. 
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